Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anna Kryzhanivska"'
Autor:
Igor Bondarenko, Viktor Stus, Jens Bedke, Ihor Vynnychenko, Mei Chen, Anna Kryzhanivska, Rustem Gafanov, Qiong Shou, Robert E. Hawkins, Maurice Markus, Sergio J Azevedo, Raymond S. McDermott, Rodolfo F. Perini, Brian I. Rini, Denis Soulières, Dmitry Nosov, Yen-Hwa Chang, Sophie Tartas, Satoshi Tamada, Delphine Borchiellini, Bohuslav Melichar, Frédéric Pouliot, Elizabeth R. Plimack, Thomas Powles, Cezary Szczylik, Michael B. Atkins, Boris Alekseev
Publikováno v:
BASE-Bielefeld Academic Search Engine
Background The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes tha
Autor:
Satoshi Tamada, Dmitry Nosov, Thomas K. Waddell, Rustem Gafanov, Raymond S. McDermott, L Rhoda Molife, J. Burgents, Chenxiang Li, Viktor Stus, Thomas Powles, Elizabeth R. Plimack, Delphine Borchiellini, Bohuslav Melichar, Frédéric Pouliot, Jens Bedke, Ihor Vynnychenko, Denis Soulières, Sergio J Azevedo, Brian I. Rini, Anna Kryzhanivska
Publikováno v:
Journal of Clinical Oncology. 39:4500-4500
4500 Background: In the first interim analysis of the randomized, multicenter, open-label, phase 3 KEYNOTE-426 study (NCT02853331), treatment with pembro + axi significantly improved OS, PFS, and ORR vs sunitinib monotherapy in treatment-naive advanc
Autor:
Thomas K. Waddell, Igor Bondarenko, Cezary Szczylik, Dmitry Nosov, Jens Bedke, Elizabeth R. Plimack, Viktor Stus, Sophie Tartas, Michael B. Atkins, Brian I. Rini, Thomas Powles, Rodolfo F. Perini, Frédéric Pouliot, Jianxin Lin, Rustem Gafanov, L Rhoda Molife, Maurice Markus, Boris Alekseev, Anna Kryzhanivska, Raymond S. McDermott
Publikováno v:
Journal of Clinical Oncology. 39:327-327
327 Background: In the randomized, open-label, phase III KEYNOTE-426 study (NCT02853331), pembrolizumab + axitinib significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) versus sunitinib as fi
Autor:
Ihor Vynnychenko, Mei Chen, Anna Kryzhanivska, Igor Bondarenko, Elizabeth R. Plimack, Thomas Powles, Michael B. Atkins, Denis Soulières, Robert E. Hawkins, Dmitry Nosov, Viktor Stus, Rustem Gafanov, Qiong Shou, Delphine Borchiellini, Bohuslav Melichar, Frédéric Pouliot, Boris Alekseev, Sergio J Azevedo, Rodolfo F. Perini, Brian I. Rini
Publikováno v:
Journal of Clinical Oncology. 37:543-543
543 Background: A phase 1b study of pembro (anti–PD-1) plus axi (VEGFR-TKI) showed promising antitumor activity and manageable safety in patients (pts) with previously untreated mRCC. The global, open-label, phase 3 KEYNOTE-426 study assessed the e